Search Results
Your search for The ASCO ,The ASCO matches 21470 pages
Showing 19851 - 19900Alexandra M. Levine, MD, MACP, Honored by LA County Medical Association
The Los Angeles County Medical Association (LACMA) awarded the Hospital Physician Leadership Award to Alexandra M. Levine, MD, MACP, Chief Medical Officer of City of Hope. Dr. Levine received the award in recognition of her exemplary contributions to the medical profession, including her leadership ...
City of Hope Provost Steven T. Rosen, MD, Honored by Israel Cancer Research Fund
Steven T. Rosen, MD, Provost and Chief Scientific Officer for City of Hope, has received a Lifetime Achievement Award from the Israel Cancer Research Fund (ICRF). The award recognizes Dr. Rosen’s longstanding commitment to advancing science and medicine and providing extraordinary patient care. Dr. ...
Practicing the Humanistic and Holistic Approach to End-of-Life Care
In 1990, when Bruce (B.J.) Miller, MD, was an undergraduate at Princeton University, the practice of medicine was far from his mind. Then a student in Chinese and Asian studies and later an art history major, Dr. Miller would come to pursue a career specializing in palliative medicine after an...
Philip W. Kantoff, MD, Named Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center
Philip W. Kantoff, MD, has been named the new Chairman of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). An accomplished leader, physician, researcher, and mentor, Dr. Kantoff served the Dana-Farber Cancer Institute and Harvard Medical School (HMS) since 1987 in a...
Montefiore and Einstein Receive $3.9 Million NCI Calabresi Grant
Montefiore Einstein Center for Cancer Care (MECCC) and the Albert Einstein Cancer Center (AECC) announced receipt of a $3.93 million grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for the prestigious Paul Calabresi Career Development Award for...
Dario Marchetti, PhD, Named Director of the Center for Biomarkers
Dario Marchetti, PhD, recently joined Houston Methodist Hospital as the new Director of the Center for Biomarkers. Over the past 7 years, Dr. Marchetti’s laboratory at Baylor College of Medicine has made key discoveries in the biology and clinical use of circulating tumor cells. Dr. Marchetti’s...
The Complex Interactions of Treatment Costs, Clinical Outcomes, and Patient Expectations
A clinical dilemma that is receiving a great deal of attention in the oncology community is the undue financial burden some patients face during their treatment and into survivorship. While much emphasis is put on methods to reduce and help patients navigate the complex payment system, little is...
UC San Diego Robotic Surgeon Christopher J. Kane, MD, Named Joseph D. Schmidt, MD, Presidential Chair in Urology
Christopher J. Kane, MD, a specialist in prostate cancer and an expert in robotic and other minimally invasive procedures for urologic surgery at the University of California, San Diego (UCSD), has been appointed the inaugural holder of the Joseph D. Schmidt, MD, Presidential Chair in Urology in...
Cancer Care in Low-Resource Areas: Some Improvements Over the Years, but Serious Problems Remain
Low- and middle-income countries bear a larger share of the global cancer burden than does the developed world,” said Greta Massetti, PhD, Associate Director for Science, Centers for Disease Control and Prevention (CDC) Division of Cancer Prevention and Control and Co-Chair of the National Cancer...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Argentina
The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Argentina. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For ...
Gut Bacteria May Facilitate Efficacy of Anti–PD-L1 Agents
Could the manipulation of bacteria in the gut pack the same punch in melanoma as antibodies targeting the programmed cell death protein and its ligand (PD-1/PD-L1)? It’s possible, at least in mice, according to research from the University of Chicago, recently published in Science.1 The researchers ...
MD Anderson Receives $22.2 Million in CPRIT Research Funding
The University of Texas MD Anderson Cancer Center was awarded more than $22 million in research grants from the Cancer Prevention and Research Institute of Texas (CPRIT). Thirty-six percent of funds awarded for Individual Investigator Awards went to MD Anderson faculty, as well as nearly 40% of...
Resource to Help Patients Manage Cancer Costs
Help your patients manage the financial impact of a cancer diagnosis with Cancer.Net’s Managing the Cost of Cancer Care booklet. This booklet provides information on the main financial categories for cancer care; an easy-to-understand explanation of health insurance benefits; information about the...
Earn MOC Points With ASCO
The American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program promotes lifelong learning and the enhancement of the clinical judgment and skills essential for high-quality patient care. ASCO supports these principles by providing a variety of opportunities for oncology...
Barriers to Oncology Careers Focused on Cancer Prevention Could Be Addressed Through Education, Research Opportunities, Advocacy
A new study in the Journal of Clinical Oncology (JCO) on the barriers facing oncology professionals to a career focus in cancer prevention found that a lack of mentors and exposure during training, unclear career path, and uncertainty regarding reimbursement caused reluctance to incorporate...
This December: Triple Your Impact
Earlier this year, Conquer Cancer Foundation (CCF) Board Member Raj Mantena, RPh, announced his intention to match individual donations to CCF dollar-for-dollar, up to $1 million, throughout the month of September. His generous support of The Campaign to Conquer Cancer—a comprehensive, $150 million ...
Now Available: Holiday Cards From the Conquer Cancer Foundation
The holiday season has officially begun, but there is still plenty of time to share in the spirit of giving on behalf of someone special. When you donate to the Conquer Cancer Foundation through cards.conquercancerfoundation.org, the Foundation will mail greeting cards or email eCertificates in...
Making a Difference for Patients: An Interview With Dr. Daniel F. Hayes, 2015–2016 President-Elect
Daniel F. Hayes, MD, FASCO, began his term as ASCO President-Elect this past June, and will serve as President in 2016–2017. A breast cancer specialist, he is Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at ...
Cancer Researchers and Clinicians Elected as 2015 AAAS Fellows
The American Association for the Advancement of Science (AAAS) Council elected 347 fellows for 2015, in recognition of their contributions to innovation, education, and scientific leadership. The tradition of electing AAAS fellows began in 1874 to recognize members for their scientifically or...
NCCN Foundation Appoints Three New Representatives to Board of Directors
The National Comprehensive Cancer Network (NCCN) Foundation has appointed three new representatives to its Board of Directors: Heather Kopecky, PhD, MBA; Marc Samuels, JD, MPH; and Susan Stein, MPH. There are currently 15 members of the Board of Directors, responsible for the strategic direction...
Nodal Irradiation in Node-Positive Breast Cancer: It Is Not Time to Change Practice
Management of the regional nodes in breast cancer has evolved from the era of the extended radical mastectomy to exclusion of axillary dissection in appropriately selected patients. Throughout this evolution, studies of nodal irradiation have been shown to improve locoregional control, usually...
ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer
As reported in the Journal of Clinical Oncology by Catherine Van Poznak, MD, and colleagues, ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer.1 The statement is based on an ASCO expert panel review...
Evidence-Based Practice Needed in End-of-Life Care
Evidence-based oncology practice is a systematic approach to problem solving for cancer care providers, characterized by the use of the best evidence currently available for clinical decision-making. Over the past several decades, the oncology community, led by its major organizations such as ASCO...
Understanding Health-Care Disparities Among Lesbian, Gay, Bisexual, and Transgender Patients to Ensure More Effective Cancer Care
A new study examining the health-care needs of lesbian, gay, bisexual, and transgender/transsexual patients has found myriad disparities in access to cancer care.1 The researchers reviewed nearly 170 papers published over the past 15 years on the health-care needs among this population. Although...
NIH Awards City of Hope $2.2 Million Grant for Investigation of Chronic Graft-vs-Host Disease
The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) has awarded a $2.2 million grant to help City of Hope researchers explore the underlying mechanisms of graft-vs-host disease, the leading cause of long-term sickness and death following...
Closing the Racial Survival Disparity Gap in Breast Cancer: Models for Change From Chicago, New York, and Beyond
It has long been said that white women of European ancestry are more likely to be diagnosed with breast cancer, but African American women are more likely to die of it. This statement has introduced multiple articles on the topic of the racial survival disparity in breast cancer, including our own...
Reducing Racial Disparities in Breast Cancer Incidence and Mortality Trends to Improve Outcomes
A recent report by DeSantis and colleagues from the American Cancer Society, summarized in this issue of The ASCO Post, presented breast cancer incidence and mortality data from an extensive analysis of the U.S. system of state-based tumor registries.1 The data showed that the incidence of breast...
Amy K. Hara, MD, Named Chair of Diagnostic Radiology at Mayo–Arizona
Amy K. Hara, MD, has been named Chair of Diagnostic Radiology at Mayo Clinic’s Arizona campus. Dr. Hara, Professor of Radiology, joined Mayo Clinic in 2001. Her main research interests include computed tomography (CT) colonography, also known as virtual colonoscopy; CT enterography; CT radiation...
FDA Approves Necitumumab Combination for Metastatic Squamous NSCLC
The FDA approved necitumumab (Portrazza) in combination with gemcitabine and cisplatin for first-line treatment of patients with metastatic squamous non–small cell lung cancer (NSCLC). Necitumumab is not indicated for treatment of nonsquamous NSCLC. Necitumumab is a recombinant human IgG1...
NCCN Names Robert C. Young, MD, Interim Vice President of Oncology Research Program
The National Comprehensive Cancer Network (NCCN) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program. Dr. Young brings to NCCN more than 45 years of oncology experience. He is President of RCY Medicine, a consulting service focused on cancer center...
Trabectedin in Liposarcoma/Leiomyosarcoma: The Drug Is Approved, Now the Real Drug Development Begins!
Led by George Demetri, MD, of Dana-Farber Cancer Institute, Boston, expert medical oncology investigators from leading academic sarcoma centers and Janssen Pharmaceuticals employees performed a phase III trial in order to provide evidence for the U.S. Food and Drug Administration (FDA) approval of...
Molecularly Targeted Therapy Brings New Hope to Patients With Relapsed/Refractory Hairy Cell Leukemia
The treatment of hairy cell leukemia is one of the great success stories in hematologic malignancies, with patients now having a survival that is only slightly inferior to an age-matched normal population. Purine analogs, such as cladribine, are the mainstay of first-line therapy, with...
Nivolumab Receives Two FDA Approvals in November
Nivolumab (Opdivo) is a monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2, releasing PD-1 pathway–mediated inhibition of the immune response. Late last month, the U.S. Food and Drug Administration (FDA)...
Clinical Trial Design in Older Patients
Geriatrics for the Oncologist is guest edited by Stuart Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Visit SIOG.org for more on geriatric oncology. Increasing age is directly associated with an increasing risk of cancer,...
FDA Approves Elotuzumab in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted approval for elotuzumab (Empliciti) in combination with two other therapies to treat patients with multiple myeloma who have received one to three prior medications. “We are continuing to learn about the ways the immune system interacts with...
2015 Review of Newly Approved Oncologic Therapies
Over the past year or so, a host of new agents were approved for the treatment of patients with various types of cancer (see related article on page 1). Patrick Medina, PharmD, of the University of Oklahoma College of Pharmacy, Oklahoma City, and Monique Giordana, PharmD, BCOP, of Regions...
Ovarian Cancer: Current Treatment and Patient Management
Tough initial treatment decisions have “long-lasting ramifications and affect the entire treatment paradigm” for women with ovarian cancer, according to Bradley J. Monk, MD, FACS, FACOG, of the University of Arizona Cancer Center, Phoenix. In a true collaborative presentation at the Annual JADPRO...
U-M Cancer Center Names Bhramar Mukherjee, PhD, Associate Director for Population Science Research
The University of Michigan (U-M) Comprehensive Cancer Center has appointed Bhramar Mukherjee, PhD, as Associate Director for Population Science Research. Dr. Mukherjee is John D. Kalbfleisch Collegiate Professor of Biostatistics and Professor of Epidemiology at the U-M School of Public Health. She...
Expert Point of View: Charles Loprinzi, MD
Charles Loprinzi, MD, Regis Professor of Breast Cancer Research, Mayo Clinic, Rochester, Minnesota, commented on these study findings to The ASCO Post: “This is a clinical application of the ghrelin agonist story that’s been brewing for maybe a decade. Is it better than megestrol acetate, the drug...
Combining Molecular-Driven Approach and Immunotherapy to Improve Treatment for Patients With Inflammatory Breast Cancer
We have a responsibility to develop better treatment for inflammatory breast cancer,” Massimo Cristofanilli, MD, FACP, told participants at the 17th Annual Lynn Sage Breast Cancer Symposium in Chicago. As recently appointed Associate Director of Translational Research and Precision Medicine at the ...
ASCO Guideline on the Use of Biomarkers in Treatment Decisions in Metastatic Breast Cancer: Shedding Light on an Often Mysterious Art
As summarized in this issue of The ASCO Post (see "ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer"), Van Poznak and colleagues recently presented an ASCO clinical practice guideline on the use of biomarkers for decisions...
Filial Gaze at Our Noble Profession
As we stood outside patient X’s room going over the vitals, from a distance, I saw the father of the patient by the side of her bed. I saw him standing there and looking down at his child conveying what I guess were words of reassurance and reinforcing the pillars of strength needed for her...
FDA Oncology New Drug/New Indication Approvals for 2015
The following new hematology/oncology agents and expanded indications were approved by the U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research in 2015: Alectinib (Alecensa), an ALK inhibitor, for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive...
Mixing Metaphors to Change the Language of Cancer
BookmarkTitle: Malignant Metaphor: Confronting Cancer MythsAuthor: Alanna MitchellPublisher: ECW PressPublication date: September 15, 2015Price: $24.95; hardcover, 184 pages Illness is the night-side of life, a more onerous citizenship. Everyone who is born holds dual citizenship, in the kingdom...
Mohamed Bentires-Alj, PharmD, PhD, Honored With 2015 AACR Outstanding Investigator Award for Breast Cancer Research
Mohamed Bentires-Alj, PharmD, PhD, was recognized with the 8th Annual American Association for Cancer Research (AACR) Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen. He received the award at the 2015 San Antonio Breast Cancer Symposium. The AACR Outstanding...
AACR Recognizes Anne-Lise Børresen-Dale, DSc, With 2015 Distinguished Lectureship in Breast Cancer Research
Anne-Lise Børresen-Dale, DSc, Professor at the University of Oslo and Head of the Department of Genetics at the University Hospital Radiumhospitalet in Oslo, Norway, was honored with the 8th Annual American Association for Cancer Research (AACR) Distinguished Lectureship in Breast Cancer Research...
Breast Care Services at Henry Ford Health System Gains New Director, Three New Surgeons
Internationally renowned breast cancer surgeon Lisa A. Newman, MD, MPH, has joined Henry Ford Health System to lead its metro Detroit breast cancer program and new international breast cancer research center. She begins work in December as the Director of the Breast Cancer Program at Henry Ford....
Expect Questions About Prostate Cancer Screening and Active Surveillance
A study finding that the incidence of prostate cancer has declined in recent years may at first seem like good news to physicians and patients, but, as widely reported by the media, the decline is not seen as an indication that prostate cancer has become less prevalent, but that screening for it...
Decline in PSA Testing and Incidence of Early Prostate Cancer Coincide With 2012 Recommendation Against PSA Screening
Two recent studies1,2 found that the rates of prostate-specific antigen (PSA) screening have declined since the U.S. Preventive Services Task Force (USPSTF) recommended against PSA screening in 2012. One of those studies additionally found that the incidence of early-stage prostate cancer also...
NIH Awards City of Hope $4.8 Million to Study Environment and Breast Cancer
The National Institutes of Health has awarded City of Hope a 5-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women. The coprincipal investigators on the study are two City of Hope...
